Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nano Xsomes
- Development stage
- Unknown
- Lead developer
- Platinum Productions
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
Nano Xsomes is a cord blood-derived exosome product developed by Platinum Biologics, specifically derived from human progenitor endothelial stem cells (hPESCs). These extracellular vesicles are designed to deliver a bioactive cargo of proteins, RNAs, growth factors (such as IGFBP 1, 2, 3, and 6, insulin, growth hormone, PDGF-AA, TGF-β1, and VEGF), and anti-inflammatory cytokines (like IL-1RA) to modulate tissue responses. Marketed for research, cosmetic, and homologous use applications—such as promoting fibroblast proliferation and inducing stem cell migration—the product is available as a lyophilized preparation containing approximately 30 billion exosomes. Notably, Nano Xsomes is not FDA-approved for the treatment of any disease; in 2025, the FDA issued a warning letter to the developer regarding the marketing of Nano Xsomes as an unapproved new drug and unlicensed biological product.
- Brand names
- Nano Xsomes
- Other names
- Cord blood-derived exosomes from hPESCs
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)PDGFR (PDGFR family)VEGFR (VEGFR family)TGFBR (TGF-beta receptor)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))
Beyond the preview
Go deeper on Nano Xsomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nano Xsomes.